Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Marcus Mall (Berlin, Germany). Novel therapeutics for cystic fibrosis. ERS Webinar 2020: Novel therapeutics for cystic fibrosis

Member's Comments

Sebnem Ozdogan - 12.01.2020 13:42
Well done

Related content which might interest you: Genotype-specific small-molecule therapy for cystic fibrosis Source: Breathe 2013; 9: 176-186 Year: 2013 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 New cystic fibrosis therapy targets Source: Research Seminar 2014 - Protein quality control in lung disease Year: 2014 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Genotype specific therapies for cystic fibrosis Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies Year: 2004 Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019 New vaccines for use in cystic fibrosis Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies Year: 2004 Neomacrolides in cystic fibrosis Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease Year: 2012 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 Novel protein biomarkers of bronchiectasis in children with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Transition in cystic fibrosis Source: International Congress 2017 – PG16 Transition of children and adolescents into adult care Year: 2017 CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019 Year: 2020